Berberine (CAS 2086-83-1): AMPK Activator & LDLR Upregulation in Metabolic Disease Models

Executive Summary: Berberine (CAS 2086-83-1) is an isoquinoline alkaloid that activates AMP-activated protein kinase (AMPK), leading to regulation of glucose and lipid metabolism in both cellular and animal models (Li et al., 2025). It upregulates low-density lipoprotein receptor (LDLR) expression in hepatoma cell lines in a dose-dependent fashion. In hyperlipidemic hamsters, oral administration at 50–100 mg/kg/day reduces serum cholesterol and LDL levels within 10 days. Berberine exhibits anti-inflammatory and antimicrobial effects, but optimal use requires strict attention to solubility and storage parameters (APExBIO). The compound's mechanisms and benchmarks support its role in translational research for metabolic, cardiovascular, and acute inflammatory disease models.

Biological Rationale

Berberine is a quaternary isoquinoline alkaloid primarily isolated from Cortex Phellodendri Chinensis. Its molecular weight is 336.36 Da, and its chemical formula is C₂₀H₁₈NO₄ (APExBIO). The compound is insoluble in water and ethanol but dissolves at ≥14.95 mg/mL in DMSO. Berberine’s principal biological activities include activation of AMPK, modulation of metabolic signaling, upregulation of LDL receptor, and suppression of pro-inflammatory processes. Its anti-inflammatory effects are relevant to diseases characterized by excessive activation of the NLRP3 inflammasome and cGAS-STING pathways, as seen in metabolic syndrome and acute kidney injury (Li et al., 2025). Berberine’s regulatory impact on glucose and lipid metabolism makes it a reference compound in diabetes, obesity, and cardiovascular disease research (adrenomedullin.us).

Mechanism of Action of Berberine (CAS 2086-83-1)

Berberine directly activates AMP-activated protein kinase (AMPK), a central regulator of energy homeostasis. AMPK activation leads to increased glucose uptake, improved insulin sensitivity, and enhanced lipid oxidation. In hepatoma cell lines (HepG2 and Bel-7402), berberine upregulates LDLR mRNA and protein expression, with maximal effects at 15 μg/mL. This upregulation facilitates hepatic clearance of LDL cholesterol from the circulation. Berberine also modulates inflammatory signaling by inhibiting the NLRP3 inflammasome and attenuating cGAS-STING-mediated responses. Indirectly, these actions reduce secondary cell death and tissue injury in models of acute inflammation (Li et al., 2025). The compound’s antimicrobial properties are attributed to its ability to disrupt microbial cell membranes and inhibit nucleic acid synthesis.

Evidence & Benchmarks

• In HepG2 and Bel-7402 cells, berberine increased LDLR mRNA and protein expression in a dose-dependent manner, with maximal induction at 15 μg/mL (incubation 24–48 h) (ddp-4.com).
• Oral administration of berberine at 50 or 100 mg/kg/day for 10 days in hyperlipidemic female golden hamsters led to significant reductions in serum total cholesterol and LDL cholesterol (p<0.01), correlated with increased hepatic LDLR expression (Li et al., 2025).
• Berberine demonstrated anti-inflammatory effects by suppressing the NLRP3 inflammasome and dampening cGAS-STING signaling in murine models of acute kidney injury (Li et al., 2025).
• Pharmacological benchmarks indicate berberine’s half-life in rodents is approximately 4–6 hours after oral dosing (50–100 mg/kg), with low oral bioavailability due to poor water and ethanol solubility (APExBIO).
• Warming to 37°C or ultrasonic shaking is required for optimal dissolution in DMSO, and stock solutions should be stored below -20°C, protected from moisture and heat (adrenomedullin.us).

This article extends the comparative mechanistic focus found in "Berberine (CAS 2086-83-1): Mechanistic Convergence and Strategy" by integrating new benchmarks from inflammasome studies. It also updates the workflows described in "Berberine (CAS 2086-83-1): AMPK Activator & LDLR Upregulation" by providing specific storage and solubility guidance for APExBIO’s product.

Applications, Limits & Misconceptions

Berberine is used as a tool compound in metabolic disease, diabetes, obesity, cardiovascular disease, and acute inflammatory models. Its validated effects on AMPK and LDLR are reproducible across human cell lines and rodent models. Berberine also exhibits antimicrobial activity, making it relevant in select infection models. However, its poor solubility in aqueous and ethanol solutions, along with low oral bioavailability, constrains its translational potential. Long-term storage of solutions is not recommended, and batch-to-batch consistency is crucial for reproducibility (APExBIO).

Common Pitfalls or Misconceptions

• Berberine is not suitable for experiments requiring high aqueous solubility without DMSO or additional solubilizing agents.
• The compound’s in vivo efficacy is limited by low oral bioavailability and rapid metabolism in rodents.
• Berberine should not be considered a first-line antimicrobial in clinical settings; its antimicrobial effects are moderate and primarily demonstrated in vitro.
• Long-term storage of berberine solutions at room temperature or above -20°C leads to degradation and loss of activity.
• Extrapolation from animal models to human clinical outcomes should be performed with caution, given differences in metabolism and pharmacokinetics.

Workflow Integration & Parameters

For laboratory use, berberine (N1368) from APExBIO should be dissolved in DMSO to a concentration of at least 14.95 mg/mL. Warming the solution to 37°C or using ultrasonic shaking optimizes dissolution. Stock solutions must be stored at or below -20°C and protected from moisture and light. Working solutions should be prepared fresh before use. In cell-based assays, effective concentrations range from 1 to 15 μg/mL, with maximal LDLR induction at 15 μg/mL after 24–48 hours. In animal studies, oral dosing of 50–100 mg/kg/day for 10 days is standard for lipid-lowering effects in hyperlipidemic models. Berberine’s half-life in rodents is 4–6 hours, and repeated dosing may be necessary for sustained effects. APExBIO’s quality control ensures batch-to-batch consistency, supporting standardized workflows (Berberine (CAS 2086-83-1) product page).

Conclusion & Outlook

Berberine (CAS 2086-83-1) is a validated AMPK activator and LDL receptor upregulator with established benchmarks in metabolic disease research. Its anti-inflammatory and metabolic effects are mechanistically linked to suppression of the NLRP3 inflammasome and cGAS-STING signaling. The compound’s reproducibility and defined handling parameters make it a reference standard for translational research. Future studies may clarify its utility in human disease models and optimize delivery strategies to overcome solubility and bioavailability limitations. For consistent results, researchers are advised to use high-quality, well-characterized sources such as APExBIO’s Berberine (N1368).